MR 409 

MR 409 is a selected growth hormone-releasing hormone (GHRH) agonist. MR 409 has remarkable neuroprotective effects through enhancing endogenous neurogenesis in cerebral ischemic mice. MR 409 also inhibits the in vivo growth of lung cancer^[1][2][3][4].

One week post-myocardial infarction (MI), MR 409 (MR-409) significantly reduces plasma levels of IL-2, IL-6, IL-10 and TNF-α compared to placebo^[1].
MR 409 (MR-409; 1 μM) suppresses p53 expression in bovine pulmonary arterial endothelial cells (BPAECs)^[2].
MR 409 (1 μM) induces the activation of JAK2, STAT3 and ERK1/2^[2].
MR 409 (MR-409; 1 and 5 μM) decreases LPS-induced PGE₂ and 8-iso-PGF_2α levels, in a dose-dependent manner^[3].
MR 409 (1 and 5μM) decreases LPS-induced lactate dehydrogenase (LDH) activity and nitrite production, without showing a dose-dependent effect^[3].
MR 409 (1 and 5 μM) decreases LPS-induced gene expression of COX-2, NF-κB and iNOS in colon specimens, without a dose-dependent effect^[3].
MR 409 (MR-409) can stimulate endogenous neurogenesis and improve the tMCAO-induced loss of neuroplasticity. MR 409 also enhances the proliferation and inhibits apoptosis of neural stem cells treated with oxygen and glucose deprivation-reperfusion^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

MR 409 (MR-409) inhibits the in vivo growth of lung cancer xenografted into nude mice^[3].
MR 409 (5 μg; s.c. treated daily for 4 weeks) reduces nociceptive response in mice^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

3395.91

C₁₅₃H₂₅₂N₄₄O₄₃

1445155-39-4

固体

White to off-white

{Asn-Me}-Tyr-{D-Ala}-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-{Orn}-Val-Leu-{Abu}-Gln-Leu-Ser-Ala-Arg-{Orn}-Leu-Leu-Gln-Asp-Ile-{Nle}-Asp-Arg-NHMe

{N-Me}-Y-{D-Ala}-DAIFTNSYR-{Orn}-VL-{Abu}-QLSAR-{Orn}-LLQDI-{Nle}-DR-NHMe

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture and light, under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

• [1]. Rosemeire M Kanashiro-Takeuchi, et al. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget. 2015;6(12):9728-39.  [Content Brief]

  [2]. Mohammad A Uddin, et al. GHRH antagonists support lung endothelial barrier function. Tissue Barriers. 2019;7(4):1669989.  [Content Brief]

  [3]. Lucia Recinella, et al. Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice. Sci Rep. 2021 Jan 28;11(1):2530.  [Content Brief]

  [4]. Yueyang Liu, et al. Agonistic analog of growth hormone-releasing hormone promotes neurofunctional recovery and neural regeneration in ischemic stroke. Proc Natl Acad Sci U S A. 2021 Nov 23;118(47):e2109600118.  [Content Brief]